Geoffrey Porges – SVB Leerink

SVB Leerink

An analyst at SVB Leerink with 15 tracked ratings across 14 distinct tickers has a 44% success rate on the captured sample, with 2 bullish ratings and 2 holds issued in the last recorded ratings.

Aggregated from multiple market-data sources

Total ratings

Tickers covered

Sources

Aggregated

Latest rating

4 years ago

2021-12-15 00:00:00+00

Track record

Aggregated

44% success rate

Bullish: 8
Hold: 4
Bearish: 2

Aggregated

Not available

Bullish: 4
Hold: 1
Bearish: 0

Recent ratings

Ticker	Date	Rating	Price target	Source
PFE	2021-12-15	sell	$56.00	Aggregated
PFEPFIZER INC.	2021-12-15	unknown	$56.00	Aggregated
RDUS	2021-12-09	buy	$20.00	Aggregated
RDUSRADIUS RECYCLING INC. - ORDINARY SHARES - CLASS A	2021-12-09	unknown	$20.00	Aggregated
RCUS	2021-11-18	buy	$100.00	Aggregated
RCUSARCUS BIOSCIENCES INC	2021-11-18	unknown	$100.00	Aggregated
AMGN

Tickers covered(25)

Ticker	Ratings	Last rating	Sources
PFE	2	2021-12-15	Aggregated
PFEPFIZER INC.	1	2021-12-15	Aggregated
RDUS	2	2021-12-09	Aggregated
RDUSRADIUS RECYCLING INC. - ORDINARY SHARES - CLASS A	1	2021-12-09	Aggregated
RCUS	2	2021-11-18	Aggregated
RCUSARCUS BIOSCIENCES INC	1	2021-11-18	Aggregated
AMGN	1	2021-11-03	Aggregated
AMGNAMGEN INC.	1	2021-11-03	Aggregated
HALO	2	2021-11-03	Aggregated
HALOHALOZYME THERAPEUTICS INC.	1	2021-11-03	Aggregated
ABBV	2	2021-10-27	Aggregated
ABBVABBVIE INC	1	2021-10-27	Aggregated
REGN	2	2021-10-26	Aggregated
REGNREGENERON PHARMACEUTICALS, INC.	1	2021-10-26	Aggregated
TBPH	2	2021-09-16	Aggregated
TBPHTHERAVANCE BIOPHARMA INC	1	2021-09-16	Aggregated
FGEN	2	2021-08-10	Aggregated
FGENFIBROGEN INC	1	2021-08-10	Aggregated
KYNB	4	2021-08-10	Aggregated
TBIO	1	2021-08-03	Aggregated
TBIOTELESIS BIO INC	1	2021-08-03	Aggregated
VRTX	2	2021-07-20	Aggregated
VRTXVERTEX PHARMACEUTICALS, INC.	1	2021-07-20	Aggregated
ASMB	3	2021-05-10	Aggregated
ASMBASSEMBLY BIOSCIENCES INC	1	2021-05-10	Aggregated

Methodology differs by source. Track records are aggregated from multiple sources; scoring methodology and scales differ by source and values are not directly comparable. Coverage is sourced from publicly-aggregated analyst activity. Past performance does not guarantee future results. Not investment advice.